Trial Profile

LONG-TERM 24-HOUR INTRAOCULAR PRESSURE CONTROL AND PROGRESSION RATE OBTAINED WITH THE ASSOCIATION OF COMBIGAN IN THE MORNING AND GANFORT IN THE EVENING COMPARED WITH LATANOPROST IN HIGH RISK OPEN-ANGLE GLAUCOMA (Controllo della pressione intraoculare nelle 24 ore e velocità di progressione della malattia ottenuto con la somministrazione di Combigan al mattino e Ganfort la sera rispetto alla somministrazione di Latanoprost la sera nei pazienti con nuova diagnosi di glaucoma ad angolo aperto o Glaucoma esfoliativo ad alto rischio di progressione)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost/timolol (Primary) ; Brimonidine/timolol (Primary) ; Latanoprost (Primary)
Indications Glaucoma
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com